VK Gadi, Lowell L. Hart, Paolo Tarantino, Priyanka Sharma, Sarah L. Sammons, Panagiotis Mavros, Maneet Kaur, Nada Boualam, Catherine Keane, Gary Mark Sopher, Purnima Pathak, Hope S. Rugo. "(RW) post-progression outcomes following first-line (1L) ribociclib (RIB) + aromatase inhibitor (AI) versus AI alone in African American and low socio-economic status (SES) patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (MBC) in US.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.1073